α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents

Kotaro Matsusaka, Yu Ishima, Hitoshi Maeda, Ryo Kinoshita, Shota Ichimizu, Kazuaki Taguchi, Victor Tuan Giam Chuang, Koji Nishi, Keishi Yamasaki, Masaki Otagiri, Hiroshi Watanabe, Toru Maruyama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α1-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.

Original languageEnglish
Pages (from-to)3592-3598
Number of pages7
JournalJournal of Pharmaceutical Sciences
Volume108
Issue number11
DOIs
Publication statusPublished - 2019 Nov

Keywords

  • DDS carrier
  • anticancer agents
  • cancer
  • orosomucoid
  • α-acid glycoprotein

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'α<sub>1</sub>-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents'. Together they form a unique fingerprint.

Cite this